Noindex: medium evidence

488-69-7

CAS 488-69-7

488-69-7 (CAS 488-69-7) is a pharmaceutical compound with 3 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
3
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
488-69-7
CAS Number
488-69-7
UNII
M7522JYX1H
InChIKey
XPYBSIWDXQFNMH-UYFOZJQFSA-N
ChEMBL ID
CHEMBL1235112
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural product
SOURCE EMBL-EBI ChEMBL 3 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Ki 38600 nM 5 -
- IC50 11500 nM 2 -
- AC50 23 nM 1 -
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is 488-69-7 used for in pharmaceutical contexts?

488-69-7 (CAS 488-69-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for 488-69-7?

No adverse-event association or SIDER side-effect rows are rendered for 488-69-7 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is 488-69-7 also used in cosmetics?

No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for 488-69-7.

What clinical phase is 488-69-7 in?

No phase 1-4 clinical development badge is rendered for 488-69-7 because the matched compound identifier rows do not contain a max-phase value.